Oct 28, 2015 by Brian Orelli, PhDWhy IDEXX Laboratories, Inc. Is in the Dog House TodayFinancial guidance from the veterinary diagnostic company was less than stellar.
Oct 27, 2015 by Brian Orelli, PhDWhy Pacific Biosciences of California Went Up, Then Down, Then SidewaysIt can be hard to value a company at its inflection point.
Oct 25, 2015 by Brian Orelli, PhDIs Profitiablity in Pacific Biosciences of California's DNA?The sequencer maker registers a profitable quarter thanks to a financial artifact.
Oct 23, 2015 by Brian Orelli, PhDWhy athenahealth Skyrocketed TodaySolid earnings numbers help the digital health company.
Oct 23, 2015 by Brian Orelli, PhDWhy Pacific Biosciences of California Jumped TodayThe sequencer maker scales the wall of worry created by its competitor.
Oct 22, 2015 by Brian Orelli, PhDBiogen's Beat, Raise, and YawnA nice turnaround for the big biotech; but is it enough?
Oct 22, 2015 by Brian Orelli, PhDWhy Valeant Pharmaceuticals Intl Inc Fell Again TodayControversies generally don't go away overnight.
Oct 21, 2015 by Brian Orelli, PhDWhy Valeant Pharmaceuticals Plummeted TodayWhen short sellers attack.
Oct 21, 2015 by Brian Orelli, PhDNatus Medical: This Baby Can LeverageIncreasing margins and decreasing "other expenses" help the medical-device maker grow earnings.
Oct 20, 2015 by Brian Orelli, PhDWhy Valeant Pharmaceuticals Fell 17% Over 2 DaysInvestors are worried about the drugmaker's future.
Oct 16, 2015 by Brian Orelli, PhDThe Lazy Way to Invest in Cancer ImmunotherapyNo biotech experience required.
Oct 16, 2015 by Brian Orelli, PhDWhy Zafgen Plummeted TodayThe FDA puts a clinical hold on the biotech's lead drug.
Oct 13, 2015 by Brian Orelli, PhDWhy Zafgen Is Down 54% Over the Last Two DaysSomeone knows something, but no one is talking.
Oct 13, 2015 by Brian Orelli, PhDWant Lower Drug Prices? These 3 Proposals Won't Help You!There's only one thing that can truly lower drug prices in a free market economy.
Oct 12, 2015 by Brian Orelli, PhDWinners and Losers of Eli Lilly's CETP Drug FailureMerck is guilty by association while other drugmakers rejoice.
Oct 7, 2015 by Brian Orelli, PhDWhy Pacific Biosciences Pushed Higher TodayThe sequencer maker highlights its new machine at the American Society of Human Genetics.
Oct 6, 2015 by Brian Orelli, PhDWhy Juno Therapeutics Jumped TodayInvestors are giddy about the biotech's prospects.
Oct 6, 2015 by Brian Orelli, PhDWhy Illumina Is Down Big TodayPreliminary third quarter revenue falls short of expectations at the sequencer maker.
Oct 5, 2015 by Brian Orelli, PhDWhy Valeant Pharmaceuticals Fell Again TodayThe drug pricing issue is still affecting the drugmaker
![8266476742_4967a82707_z_d[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F181865%2F8266476742_4967a82707_z_d1.jpg&w=384&op=resize)